Consensus $16.05. Backs FY25 revenue view up 6.7%-8%. The company said, “Labcorp (LH) is updating 2025 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2025, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Notable companies reporting before tomorrow’s open
- LH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Labcorp Holdings: Buy Rating Maintained Amid Minimal Impact from FDA’s Animal Testing Phase-Out
- Labcorp price target lowered to $274 from $285 at Truist
- Labcorp Holdings Declares Cash Dividend for Shareholders
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue